Saracatinib, Potential Oral IPF Therapy, Granted Orphan Drug Status by FDA
Saracatinib (AZD0530), an investigational oral therapy under development by AstraZeneca, was granted Orphan Drug Designation as a potential treatment for idiopathic pulmonary fibrosis (IPF) by the U.S. Food and Drug…